论文部分内容阅读
目的:探讨胰腺癌组织微血管密度、p14~(ARF)表达对胰腺癌发生、发展的影响。方法:用免疫组织化学Envision改良法检测10例正常胰腺组织、42例胰腺癌组织中p14~(ARF)蛋白的表达;以Ⅷ因子相关抗原(FVⅢ-RAg)标记血管内皮细胞,采用ABC免疫组化法检测10例正常胰腺组织、42例胰腺癌组织中微血管密度。结果:正常胰腺组织中p14~(ARF)的表达率为90％,胰腺癌组织中为35.7％(P<0.01);胰腺癌组织的平均微血管密度与正常对照组之间差异有显著性(P<0.01);胰腺癌临床Ⅲ、Ⅳ期的平均微血管密度明显高于Ⅰ、Ⅱ期(P<0.05);淋巴结有转移的胰腺癌平均微血管密度明显高于淋巴结无转移组(P<0.05);胰腺癌组织中p14~(ARF)蛋白阳性表达的平均微血管密度低于p14~(ARF)蛋白阴性表达的胰腺癌组织,差异有显著性(P<0.05),胰腺癌组织的平均微血管密度与组织学分级、癌的浸润范围及肿块大小无关(P>0.05)。结论:微血管密度、p14~(ARF)与胰腺癌的发生、发展存在着密切关系。
Objective: To investigate the effect of microvessel density and p14 ARF expression on the occurrence and development of pancreatic cancer. METHODS: Immunohistochemistry Envision method was used to detect the expression of p14 ARF protein in 10 normal pancreatic tissues and 42 pancreatic cancer tissues; vascular endothelial cells were labeled with VIII factor-associated antigen (FVIII-RAg) and ABC immunization group was used. The method was used to detect microvessel density in 10 normal pancreatic tissues and 42 pancreatic cancer tissues. Results: The expression rate of p14 ARF was 90% in normal pancreatic tissues and 35.7% in pancreatic cancer tissues (P<0.01). The average microvessel density in pancreatic cancer tissues was significantly different from that in normal controls (P<0.05). <0.01); The average microvessel density in stage III and IV of pancreatic cancer was significantly higher than that of stage I and II (P<0.05); the average microvessel density of pancreatic cancer with lymph node metastasis was significantly higher than that of lymph node metastasis (P<0.05). The average microvessel density of pancreatic adenocarcinoma tissue was lower than that of pancreatic cancer tissue with negative expression of p14 ARF protein (P<0.05). The mean microvessel density and tissue in pancreatic cancer tissues were also found. The grade of learning, the extent of invasion of the tumor and the size of the tumor were irrelevant (P > 0.05). Conclusion: There is a close relationship between microvessel density, p14 ARF and the occurrence and development of pancreatic cancer.